K2LT Enterprise is valued at 50 million US dollars, and this angel round plans to raise 9 million US dollars at a stock price of 2 US dollars per share, which will be used for global sales network expansion, company team expansion, and subsequent research and development; After meeting the listing requirements, the company will complete its stock listing on the NASDAQ Main Board in the United States through IPO or SPAC. Investors who enter this round will receive an expected capital return of about 25 times.


These established markers provide a blueprint for what measures we can take to slow down the deterioration process of aging, and also provide strong theoretical support for the K2LT laboratory!